Ciprofloxacin is a member of the fluoroquinolone class of antibacterial agents.

CIPRO is a fluoroquinolone antibacterial indicated in adults (18 years of age and older) with the following infections caused by designated, susceptible bacteria and in pediatric patients where indicated: Skin and Skin Structure Infections, Bone and Joint Infections, Complicated Intra-Abdominal Infections, Infectious Diarrhea, Typhoid Fever (Enteric Fever), Uncomplicated Cervical and Urethral Gonorrhea, Inhalational Anthrax post-exposure in adult and pediatric patients, Plague in adult and pediatric patients, Chronic Bacterial Prostatitis, Lower Respiratory Tract Infections (See Full Prescribing Information).

The determination of dosage and duration for any particular patient must take into consideration the severity and nature of the infection, the susceptibility of the causative microorganism, the integrity of the patient’s host-defense mechanisms, and the status of renal and hepatic function. CIPRO Tablets or CIPRO for Oral Suspension may be administered to adult patients when clinically indicated at the discretion of the physician. Administer CIPRO for Oral Suspension using the co-packaged graduated spoon. (See Full Prescribing Information.)

The most common adverse reactions ≥1% were nausea, diarrhea, liver function tests abnormal, vomiting, and rash.

CIPRO is contraindicated in persons with a history of hypersensitivity to ciprofloxacin, any member of the quinolone class of antibacterials, or any of the product components.

Hypersensitivity and other serious reactions: Serious and sometimes fatal reactions (for example, anaphylactic reactions) may occur after the first or subsequent doses of CIPRO. Discontinue CIPRO at the first sign of skin rash, jaundice or any sign of hypersensitivity. Hepatotoxicity: Discontinue immediately if signs and symptoms of hepatitis occur. Clostridioides difficile-associated diarrhea: Evaluate if colitis occurs. QT Prolongation: Prolongation of the QT interval and isolated cases of torsade de pointes have been reported. Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval.